...
首页> 外文期刊>Oncogene >The proto-oncogene Pim-1 is a target of miR-33a
【24h】

The proto-oncogene Pim-1 is a target of miR-33a

机译:原癌基因Pim-1是miR-33a的靶标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR-33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3鈥?untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.
机译:组成型活性丝氨酸/苏氨酸激酶Pim-1在不同类型的癌症中上调,主要基于几种白介素和生长因子在转录水平上的作用。到目前为止,尚未报道过microRNA(miRNA)对致癌Pim-1的调控。在这里,我们新建立了miR-33a作为具有潜在肿瘤抑制活性的miRNA,通过抑制Pim-1发挥作用。在K562淋巴瘤,LS174T结肠癌和其他几种细胞系中进行miRNA表达的筛查显示,相对于其他miRNA,内源性miR-33a水平通常较低。用miR-33a模拟物转染K562和LS174T细胞可显着降低Pim-1水平。相反,被预测为保守的miR-33a靶标的细胞周期调节细胞周期蛋白依赖性激酶6并未被miR-33a模拟物下调。萤光素酶报告基因构建体中Pim-1 3'非翻译区和Pim-1缺陷Skov-3细胞中表达的Pim-1 cDNA的种子诱变表明,miR-33a模拟物特异性且直接下调了Pim-1。 。这种作用的持久性与小干扰RNA介导的Pim-1敲低的持久性相当,导致细胞增殖减速。总之,我们证明了miR-33a可能充当抑癌miRNA,这表明通过递送miR模拟物作为新的治疗策略,miR-33a替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号